U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
NDA FilingecopipamPositive
AI Analysis
Summary
Teva Pharmaceuticals announced FDA acceptance of its NDA for ecopipam, a first-in-class therapy for pediatric Tourette Syndrome, with a PDUFA decision date targeted for late Q1 2027 under Priority Review.
Outcome Details
FDA accepted NDA with Priority Review granted
Importance:8/10
Sentiment:
0.80
FDANDAPriority ReviewFirst-in-ClassNeurosciencePediatric
Related Companies
Read the original article
Published by GlobeNewswire Pharma on August 19, 2026 12:30 PM